MedTrace Logo

Effect of Vitamin D on Morbidity and Mortality of the COVID-19

NCT04552951 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2020-09-17

No results posted yet for this study

Summary

Patients diagnosed of COVID-19 disease are randomized to receive a single dose of 100.000 IU of Cholecalciferol (Vitamin D arm) or no vitamin D (on top of the current medication used to treat COVID 19).

Clinical, radiological and biochemical outcomes of COVID 19 disease as well as mortality are evaluated.

Conditions

Interventions

DRUG

Cholecalciferol

Single doe of 100.000 IU

Sponsors & Collaborators

  • Hospital Universitario Central de Asturias

    collaborator OTHER

  • Instituto de Investigación Sanitaria del Principado de Asturias

    collaborator UNKNOWN

  • Fundación para la Investigación Biosanitaria del Principado de Asturias

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-04
Primary Completion
2020-09-14
Completion
2020-12-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04552951 on ClinicalTrials.gov